Invent Medic Sweden (IMS) Q4 2025 earnings summary

Executive summary

• Full-year sales increased slightly year-over-year, with a significant improvement in margins and reduced losses, reflecting successful strategic priorities and operational improvements.

• Focused on building scalable structures and partnerships, especially in key markets like the UK and Norway, and strengthening presence in Sweden.

• After year-end, a directed share issue raised SEK 2.3 million, improving financial flexibility and signaling distributor confidence.

Financial highlights

• Q4 2025 net sales: SEK 1,757k (Q4 2024: SEK 2,056k); full-year 2025: SEK 7,404k (2024: SEK 7,345k).

• Q4 2025 pre-tax result: SEK -1,113k (Q4 2024: SEK -2,458k); full-year 2025: SEK -5,201k (2024: SEK -7,652k).

• Q4 EPS: SEK -0.01 (Q4 2024: SEK -0.04); full-year EPS: SEK -0.05 (2024: SEK -0.11).

• Cash at year-end: SEK 501k (2024: SEK 1,248k).

• Q4 operating expenses: SEK -2,765k (Q4 2024: SEK -3,868k); full-year investments in intangibles: SEK 20k (2024: SEK 161k).

Outlook and guidance

• Positioned for profitable growth with a clear strategy focused on existing products, key markets, and strong partnerships.

• Ongoing efforts to reach break-even through organic growth and increased sales in selected markets.